Table 5 Hazard ratios for all-cause mortality during the 3-year follow-up after treatment initiationa, mRCC patients, Estonia 2004–2012
From: Changes in therapy and survival of metastatic renal cell carcinoma in Estonia
Crude HR | 95% CI | Adjustedb HR | 95% CI | Adjustedb HR | 95% CI | |
|---|---|---|---|---|---|---|
Treatment group | ||||||
Group 2c | 1.00 | 1.00 | 1.00 | |||
Group 1d | 2.29 | 1.79–2.92 | 2.15 | 1.65–2.79 | 3.88 | 2.64–5.72 |
Age group | ||||||
15–59 | 1.00 | 1.00 | 1.00 | |||
60–69 | 0.83 | 0.63–1.11 | 0.89 | 0.67–1.19 | 0.85 | 0.64–1.14 |
70+ | 0.94 | 0.71–1.26 | 0.96 | 0.71–1.28 | 0.87 | 0.64–1.17 |
Sex | ||||||
Male | 1.00 | 1.00 | 1.00 | |||
Female | 0.73 | 0.57–0.94 | 0.70 | 0.54–0.91 | 0.71 | 0.55–0.93 |
Histology | ||||||
Clear Cell | 1.00 | 1.00 | 1.00 | |||
Non clear cell | 2.00 | 1.49–2.69 | 1.36 | 0.99–1.87 | 1.48 | 1.07–2.04 |
Nephrectomy | ||||||
Done | 1.00 | 1.00 | 1.00 | |||
Not done | 1.90 | 1.41–2.57 | 1.62 | 1.19–2.21 | 1.53 | 1.12–2.09 |
Treatment period | ||||||
2004–2007 | 1.00 | – | 1.00 | |||
2008–2012 | 0.81 | 0.63–1.03 | – | 2.22 | 1.52–3.24 | |